Connect with us


US pharmaceutical company to start rollout of diabetes management platform



The American pharmaceutical company Eli Lilly and Company has announced the rollout of its diabetes management platform in the US later this year.

The technology aims to help clinicians and adults living with type one or type two diabetes make informed decisions to manage treatment.

The platform consists of three components – the reusable medical device Tempo Smart Button, a compatible app and a prefilled insulin pen – which work together to deliver guidance for adults with diabetes.

The Smart Button was cleared by the US Food and Drug Administration (FDA) in September.

Healthcare providers will have access to a clinician hub where they can access data shared by their patients through the app and track patients’ progress.

“Lilly has over a century of knowledge of insulin and its complexities, and recognises the emotional impact of managing diabetes,” said Kevin Cammack, head of connected care at Lilly Diabetes.

“Launching this platform is an opportunity for us to more broadly support those who rely on our insulins.”

The Tempo Smart Button is a reusable medical device that attaches to the top of a Tempo Pen. When paired via Bluetooth, the Smart Button is intended to detect, store and transfer insulin dose-related data to the compatible app.

The company says the app will record insulin dose information and facilitate data sharing between adults with diabetes and the healthcare providers who treat them.

Adults with diabetes can access insulin dose information and features through TempoSmart, including medication reminders, education resources, feedback on blood glucose levels, integration with Dexcom Continuous Glucose Monitoring (CGM) systems and compatibility to sync data with wearable devices such as Fitbit, Google Fit and Apple Health.

“Despite technological advancements, people continue to experience challenges with the complexities of insulin dosing” said Cammack.

“Using the learnings from early adopters of Tempo, we look forward to continually innovating our technology to aid those who use Lilly insulins to manage their diabetes.”

Lilly will conduct a phased rollout for the platform to select clinics starting later this year, followed by national availability targeted for 2023.

Continue Reading
1 Comment

1 Comment

  1. Pingback: LumiraDx continues expansion of HbA1c test

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories